{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:35:00Z","timestamp":1773851700283,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"DOI":"10.1186\/s12959-026-00840-1","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:18:40Z","timestamp":1770887920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hematologic safety of caplacizumab in immune-mediated thrombotic thrombocytopenic purpura: insights from platelet-related signal detection in the FAERS database"],"prefix":"10.1186","volume":"24","author":[{"given":"Zhenqi","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"840_CR1","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","volume":"129","author":"BS Joly","year":"2017","unstructured":"Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129:2836\u201346. https:\/\/doi.org\/10.1182\/blood-2016-10-709857.","journal-title":"Blood"},{"key":"840_CR2","doi-asserted-by":"publisher","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","volume":"3","author":"JA Kremer Hovinga","year":"2017","unstructured":"Kremer Hovinga JA, Coppo P, L\u00e4mmle B, et al. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers. 2017;3:17020. https:\/\/doi.org\/10.1038\/nrdp.2017.20.","journal-title":"Nat Rev Dis Primers"},{"key":"840_CR3","doi-asserted-by":"publisher","unstructured":"Mingot CME, Pascual IC, Gonz\u00e1lez A, et al. Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura. Med Clin (Barc). 2022;158:630.e1\u2013630.e14. https:\/\/doi.org\/10.1016\/j.medcli.2021.03.040.","DOI":"10.1016\/j.medcli.2021.03.040"},{"key":"840_CR4","doi-asserted-by":"publisher","unstructured":"Zheng XL, Al-Housni Z, Cataland SR, et al. 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2025;0. https:\/\/doi.org\/10.1016\/j.jtha.2025.06.002.","DOI":"10.1016\/j.jtha.2025.06.002"},{"key":"840_CR5","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374:511\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1505533.","journal-title":"N Engl J Med"},{"key":"840_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380:335\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1806311.","journal-title":"N Engl J Med"},{"key":"840_CR7","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1016\/S2352-3026(18)30115-7","volume":"5","author":"The Lancet Haematology null","year":"2018","unstructured":"The Lancet Haematology null. The fda\u2019s definitions, designations, and drug approvals: too daring? Lancet Haematol. 2018;5:e321. https:\/\/doi.org\/10.1016\/S2352-3026(18)30115-7.","journal-title":"Lancet Haematol"},{"key":"840_CR8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/14740338.2024.2376686","volume":"24","author":"Y Huo","year":"2025","unstructured":"Huo Y, Ma M, Liao X. Data mining study on adverse events of Tirzepatide based on FAERS database. Exp Opin Drug Saf. 2025;24:675\u201383. https:\/\/doi.org\/10.1080\/14740338.2024.2376686.","journal-title":"Exp Opin Drug Saf"},{"key":"840_CR9","doi-asserted-by":"publisher","unstructured":"Grada A, Xing C. (2025) Disproportionality analysis and the evaluation of drug safety Signals. J invest dermatol S0022-202X(25)00472\u20135. https:\/\/doi.org\/10.1016\/j.jid.2025.04.023.","DOI":"10.1016\/j.jid.2025.04.023"},{"key":"840_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s43441-024-00705-7","volume":"59","author":"S Chakraborty","year":"2025","unstructured":"Chakraborty S, Tiwari R. A clustering ensemble method for drug safety signal detection in Post-Marketing surveillance. Ther Innov Regul Sci. 2025;59:89\u2013101. https:\/\/doi.org\/10.1007\/s43441-024-00705-7.","journal-title":"Ther Innov Regul Sci"},{"key":"840_CR11","unstructured":"The reporting odds. ratio and its advantages over the proportional reporting ratio - Rothman\u2009\u2013\u20092004 - Pharmacoepidemiology and Drug Safety - Wiley Online Library. https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1001. Accessed 27 July 2025."},{"key":"840_CR12","unstructured":"Use of proportional reporting. ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports - Evans\u2009\u2013\u20092001 - Pharmacoepidemiology and Drug Safety - Wiley Online Library. https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.677. Accessed 27 July 2025."},{"key":"840_CR13","doi-asserted-by":"crossref","unstructured":"Dissimilar Hepatotoxicity Profiles of Propylthiouracil and Methimazole in. Children | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic. https:\/\/academic.oup.com\/jcem\/article-abstract\/95\/7\/3260\/2596315?redirectedFrom=fulltext%26login=false. Accessed 27 July 2025.","DOI":"10.1210\/jc.2009-2546"},{"key":"840_CR14","unstructured":"A Bayesian neural. network method for adverse drug reaction signal generation | European Journal of Clinical Pharmacology. https:\/\/link.springer.com\/article\/10.1007\/s002280050466. Accessed 27 July 2025."},{"key":"840_CR15","doi-asserted-by":"crossref","unstructured":"Chen H, Ding Y, Shan Y. Post-marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database. Expert Opinion on Drug Safety; 2025.","DOI":"10.1080\/14740338.2025.2465872"},{"key":"840_CR16","doi-asserted-by":"crossref","unstructured":"Zhao K, Xiao S, Zhao Y, Tu C. Comprehensive post-marketing safety analysis of tildrakizumab: insights from the FDA adverse event reporting system. Expert Opinion on Drug Safety; 2025.","DOI":"10.1080\/14740338.2025.2520422"},{"key":"840_CR17","unstructured":"George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014. https:\/\/www.nejm.org\/doi\/abs\/10.1056\/NEJMra1312353. Accessed 11 Aug 2025."},{"key":"840_CR18","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.jacc.2009.05.074","volume":"54","author":"JS Berger","year":"2009","unstructured":"Berger JS, Bhatt DL, Cannon CP, et al. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol. 2009;54:1935\u201345. https:\/\/doi.org\/10.1016\/j.jacc.2009.05.074.","journal-title":"J Am Coll Cardiol"},{"key":"840_CR19","doi-asserted-by":"publisher","unstructured":"Liu S, Yuan Z, Rao S, et al. Adverse drug reactions related to methotrexate: a real-world pharmacovigilance study using the FAERS database from 2004 to 2024. Front Immunol. 2025;16. https:\/\/doi.org\/10.3389\/fimmu.2025.1586361.","DOI":"10.3389\/fimmu.2025.1586361"},{"key":"840_CR20","doi-asserted-by":"publisher","unstructured":"Maqsood MH, Rubab K, Maqsood MZ. Clinical efficacy and safety profile of Caplacizumab for acquired thrombotic thrombocytopenic purpura. Cureus 11:e5263. https:\/\/doi.org\/10.7759\/cureus.5263.","DOI":"10.7759\/cureus.5263"},{"key":"840_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2023.103722","author":"M Albanell-Fern\u00e1ndez","year":"2023","unstructured":"Albanell-Fern\u00e1ndez M, Monge-Escart\u00edn I, Mart\u00edn EC-S, et al. Real-world data of the use and experience of Caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura: case series. Transfus Apheres Sci 62. 2023. https:\/\/doi.org\/10.1016\/j.transci.2023.103722.","journal-title":"Transfus Apheres Sci"},{"key":"840_CR22","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12185-022-03495-6","volume":"117","author":"Y Miyakawa","year":"2023","unstructured":"Miyakawa Y, Imada K, Ichikawa S, et al. The efficacy and safety of Caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2\/3 study. Int J Hematol. 2023;117:366\u201377. https:\/\/doi.org\/10.1007\/s12185-022-03495-6.","journal-title":"Int J Hematol"},{"key":"840_CR23","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1111\/jth.15892","volume":"20","author":"M Scully","year":"2022","unstructured":"Scully M, Rubia J, de la, Pavenski K, et al. Long-term follow\u2010up of patients treated with Caplacizumab and safety and efficacy of repeat Caplacizumab use: Post\u2010HERCULES study. J Thromb Haemost. 2022;20:2810\u201322. https:\/\/doi.org\/10.1111\/jth.15892.","journal-title":"J Thromb Haemost"},{"key":"840_CR24","doi-asserted-by":"publisher","first-page":"102654","DOI":"10.1016\/j.rpth.2024.102654","volume":"9","author":"AA Mahmoud","year":"2025","unstructured":"Mahmoud AA, Mostafa M, Abdelhay A, et al. Characterization of bleeding in thrombotic thrombocytopenic purpura in the precaplacizumab era: a retrospective nationwide analysis. Res Pract Thromb Haemostasis. 2025;9:102654. https:\/\/doi.org\/10.1016\/j.rpth.2024.102654.","journal-title":"Res Pract Thromb Haemostasis"},{"key":"840_CR25","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1182\/blood.2020007599","volume":"137","author":"T Dutt","year":"2021","unstructured":"Dutt T, Shaw RJ, Stubbs M, et al. Real-world experience with Caplacizumab in the management of acute TTP. Blood. 2021;137:1731\u201340. https:\/\/doi.org\/10.1182\/blood.2020007599.","journal-title":"Blood"},{"key":"840_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.70005","author":"M Robert","year":"2025","unstructured":"Robert M, Mageau A, Benhamou Y, et al. Anti-ADAMTS13 antibodies trajectory is associated with ADAMTS13 recovery in immune-mediated TTP. Am J Hematol. 2025. https:\/\/doi.org\/10.1002\/ajh.70005.","journal-title":"Am J Hematol"},{"key":"840_CR27","unstructured":"The Sleep-Immune Crosstalk in Health. and Disease | Physiological Reviews | American Physiological Society. https:\/\/journals.physiology.org\/doi\/full\/10.1152\/physrev.00010.2018?rfr_dat=cr_pub++0pubmed%26url_ver=Z39.88-2003%ED%94%AF_id=ori%3Arid%3Acrossref.org. Accessed 19 Aug 2025."},{"key":"840_CR28","doi-asserted-by":"publisher","unstructured":"Al-Mashdali AF, Salih SM, Vatsyayan PA, et al. Caplacizumab for pediatric immune thrombotic thrombocytopenic purpura: a scoping review of current evidence. Blood Rev. 2025;101326. https:\/\/doi.org\/10.1016\/j.blre.2025.101326.","DOI":"10.1016\/j.blre.2025.101326"},{"key":"840_CR29","doi-asserted-by":"publisher","first-page":"6561","DOI":"10.3390\/jcm13216561","volume":"13","author":"L Fianchi","year":"2024","unstructured":"Fianchi L, Bonanni M, Borchiellini A, et al. Real-World data on effectiveness and safety of First-Line use of Caplacizumab in Italian centers for the treatment of thrombotic thrombocytopenic purpura: the Roscapli study. J Clin Med. 2024;13:6561. https:\/\/doi.org\/10.3390\/jcm13216561.","journal-title":"J Clin Med"},{"key":"840_CR30","unstructured":"Effectiveness and safety of caplacizumab in. acquired thrombotic thrombocytopenic purpura: health technology assessment and classification according to the methodology established in Colombia | International Journal of Technology Assessment in Health Care|Cambridge Core. https:\/\/www.cambridge.org\/core\/journals\/international-journal-of-technology-assessment-in-health-care\/article\/effectiveness-and-safety-of-caplacizumab-in-acquired-thrombotic-thrombocytopenic-purpura-health-technology-assessment-and-classification-according-to-the-methodology-established-in-colombia\/D9DE16D23041426F79CA3A4791B958C3. Accessed 19 Aug 2025."},{"key":"840_CR31","doi-asserted-by":"publisher","first-page":"102512","DOI":"10.1016\/j.rpth.2024.102512","volume":"8","author":"K Pavenski","year":"2024","unstructured":"Pavenski K, Scully M, Coppo P, et al. Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura. Res Pract Thromb Haemost. 2024;8:102512. https:\/\/doi.org\/10.1016\/j.rpth.2024.102512.","journal-title":"Res Pract Thromb Haemost"},{"key":"840_CR32","unstructured":"Huang X-W, Chakraborty S. A nonparametric bayesian Local-Global model for enhanced adverse event signal detection in Spontaneous Reporting System Data. 2025."},{"key":"840_CR33","doi-asserted-by":"crossref","unstructured":"Tan Y, Markatou M, Chakraborty S. Flexible empirical bayesian approaches to pharmacovigilance for simultaneous signal detection. and Signal Strength Estimation in Spontaneous Reporting Systems Data; 2025.","DOI":"10.1002\/sim.70195"},{"key":"840_CR34","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10:796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048.","journal-title":"Int J Med Sci"},{"key":"840_CR35","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427\u201336. https:\/\/doi.org\/10.1002\/pds.1742.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-026-00840-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00840-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00840-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:19:29Z","timestamp":1773829169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12959-026-00840-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["840"],"URL":"https:\/\/doi.org\/10.1186\/s12959-026-00840-1","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study was based on publicly available, de-identified data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and therefore did not require ethics committee approval or informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}